Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID vs ANTURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
FDA: Treatment of hyperuricemia associated with gout (prophylaxis and chronic management), adjunct to penicillin or cephalosporin therapy to elevate and prolong antibiotic levels.,Off-label: Prevention of nephropathy in patients with hyperuricemia, adjunct to antiviral agents (e.g., cidofovir) to reduce nephrotoxicity.
Treatment of chronic gout,Prophylaxis of acute gouty attacks during initiation of allopurinol or uricosuric therapy,Off-label: Prevention of calcium oxalate calculi in hyperuricosuric patients
Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.
200-400 mg orally twice daily
Terminal elimination half-life is approximately 6-12 hours in adults with normal renal function; may be prolonged in renal impairment or older adults.
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Primarily hepatic via oxidation and glucuronidation; minor renal metabolism.
Primarily hepatic oxidation and glucuronidation; minor CYP450 involvement.
Renal excretion of unchanged drug and metabolites; ~77% of dose recovered in urine within 48 hours (50% as glucuronide conjugates, 27% as unchanged probenecid); ~11% excreted in feces via biliary elimination.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Approximately 75-95% bound to plasma albumin.
99% bound, primarily to albumin.
Apparent volume of distribution is about 9 L (approximately 0.13 L/kg in adults); indicates limited extravascular distribution, primarily confined to plasma and extracellular fluid.
0.15–0.3 L/kg, indicating limited extravascular distribution; primarily remains in plasma and extracellular fluid.
Oral bioavailability is nearly complete (>90%) with peak plasma concentrations achieved within 2-4 hours.
Oral: Approximately 90% absorbed, but extensive first-pass metabolism reduces systemic bioavailability of parent drug to 30–40%; active sulfide metabolite contributes to efficacy.
GFR 10-50 m L/min: 250 mg once daily or 500 mg every 12-24 hours; GFR <10 m L/min: avoid use; anuria: contraindicated.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-50 m L/min, reduce dose by 50%. For Cr Cl >50 m L/min, no adjustment.
No specific adjustment recommended; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
For gout or hyperuricemia (children >2 years): 25 mg/kg/day (max 2 g/day) divided every 6-8 hours; as adjunct to penicillin/cephalosporin: 25 mg/kg/day (max 2 g/day) divided every 8 hours for infants >3 months and children; neonates: dose not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lowest dose (250 mg once daily) due to age-related renal impairment; monitor renal function regularly; avoid if GFR <30 m L/min.
Start at low end of dosing range (200 mg twice daily); monitor renal function. Caution due to increased sensitivity and renal impairment.
None.
None.
Use with caution in patients with peptic ulcer disease.,May worsen acute gouty arthritis; prophylactic colchicine or NSAIDs recommended during initiation.,Risk of uric acid stone formation; ensure adequate hydration and alkalinize urine if needed.,Avoid use in patients with blood dyscrasias or bone marrow depression.,May interfere with urine glucose and ketone tests.
Acute gouty attacks may occur during initiation; prophylactic colchicine or NSAIDs recommended,Monitor renal function; dose adjustment in renal impairment,Avoid in patients with high urinary uric acid output to prevent uric acid stones,May potentiate warfarin; monitor INR,Cross-allergenicity with sulfonamides possible
Hypersensitivity to probenecid or any component.,Severe renal impairment (Cr Cl <50 m L/min) or anuria.,History of uric acid kidney stones.,Concomitant use with methotrexate (increases methotrexate toxicity).,Use during acute gouty attack (unless already on therapy).
Severe renal impairment (Cr Cl <50 m L/min),History of hypersensitivity to sulfinpyrazone or sulfonamides,Active peptic ulcer disease,Blood dyscrasias,Uric acid nephropathy or stone formation
Avoid high-purine foods (organ meats, sardines, anchovies, shellfish, red meat) as they increase uric acid levels. Limit alcohol, especially beer and spirits, which increase uric acid. Maintain high fluid intake (water, citrus juices) to promote urine flow and prevent stones. Avoid cranberry juice as it may acidify urine.
Avoid alcohol as it increases uric acid levels and may decrease drug efficacy. Maintain adequate hydration; avoid excessive intake of high-purine foods (e.g., organ meats, sardines, anchovies) to help control gout.
Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known teratogenic effects. Second and third trimesters: No specific fetal risks documented; avoid near term due to potential for neonatal hyperbilirubinemia (displaces bilirubin from albumin).
Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. However, due to its potential to inhibit platelet aggregation, use during pregnancy, especially near term, may increase the risk of maternal and fetal hemorrhage. First trimester: No specific fetal risks identified, but caution advised. Second trimester: Risks unclear; avoid unless necessary. Third trimester: Potential for premature closure of ductus arteriosus (unlikely as it is not an NSAID) and bleeding risk; avoid near term.
Probenecid is excreted into breast milk in low concentrations; M/P ratio not available. Consider benefits of breastfeeding versus potential risk of adverse effects in infant (e.g., rash, gastrointestinal effects). Use with caution.
Sulfinpyrazone is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not well established but is likely low (<0.2). Due to potential adverse effects in the nursing infant (e.g., bleeding risk, interference with platelet function), caution is recommended. The benefits of breastfeeding should be weighed against the potential risks, and alternative therapies considered.
No formal pharmacokinetic studies during pregnancy. Dose adjustment not routinely recommended, but consider decreased efficacy due to increased renal clearance in pregnancy. Monitor clinical response and adjust dose if needed.
Pregnancy can alter pharmacokinetics of drugs due to increased plasma volume, renal blood flow, and hepatic metabolism. For sulfinpyrazone, no specific dose adjustment guidelines are established for pregnancy. Given its uricosuric action, the increased glomerular filtration rate during pregnancy may enhance clearance, potentially requiring higher doses to maintain therapeutic effect. However, due to potential risks, use should be avoided if possible. If used, monitor serum uric acid levels and adjust dose accordingly, starting with the lowest effective dose.
Probenecid inhibits renal tubular secretion of uric acid, increasing its excretion; used for chronic gout, not acute attacks. It also reduces renal excretion of penicillins and cephalosporins, so it is used to increase serum levels of these antibiotics. Ensure adequate hydration (at least 2-3 L daily) to prevent urate nephropathy. Avoid in patients with creatinine clearance <50 m L/min, history of uric acid stones, or acute gout attack. Alkalinization of urine (urine p H 6.5-7) reduces stone risk. Monitor serum uric acid, renal function, and CBC. Drug interactions: potentiates toxicity of methotrexate, NSAIDs, thiazides, salicylates (salicylates antagonize uricosuric effect).
Anturane (sulfinpyrazone) is a uricosuric agent used for chronic gout. It is contraindicated in patients with peptic ulcer disease due to GI irritation. Monitor renal function and uric acid levels. Avoid use in patients with a history of uric acid stones; maintain high fluid intake to prevent stone formation. Not effective in acute gout attacks. Discontinue at least 48 hours before surgery to avoid bleeding risk due to antiplatelet effects.
Take probenecid with food or antacids to reduce GI upset.,Drink at least 8-10 glasses of water daily while on this medication.,Do not take aspirin or other salicylates; they can reduce the effect.,This drug may increase bleeding risk if you take blood thinners like warfarin.,Report any signs of allergic reaction, rash, or fever immediately.,Avoid alcohol as it increases uric acid levels.,Tell your doctor before taking other medications, especially antibiotics.,Do not use during an acute gout attack; wait until attack resolves.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Store at room temperature, away from moisture and heat.
Take with food or milk to reduce stomach upset.,Drink at least 8 glasses of water daily to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce drug effectiveness.,Report any signs of bleeding (bruising, black stools) or stomach pain.,Do not stop suddenly without consulting your doctor.,This drug is not for acute gout attacks; continue other medications as prescribed.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID vs ANTURANE, answered by our medical review team.
PROBENECID is a Uricosuric that works by Inhibits renal tubular reabsorption of uric acid, increasing its excretion and lowering serum urate levels. Also inhibits renal tubular secretion of weak acids (e.g., penicillins, cephalosporins).. ANTURANE is a Uricosuric that works by Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID and ANTURANE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID is: Oral: 250 mg twice daily for 1 week, then 500 mg twice daily; for gout prophylaxis, initial 250 mg twice daily for 3-4 weeks then increase to 500 mg twice daily; for hyperuricemia secondary to thiazide diuretics, 250 mg twice daily.. The standard adult dose of ANTURANE is: 200-400 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID and ANTURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID is classified as Category A/B. Probenecid is FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but no adequate human studies exist. Use only if clearly needed. First trimester: No known . ANTURANE is classified as Category C. Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.